This was presented during the Insight 17' event - Coimbatore / India (October 2017). Some questions were discussed concerning the Social Egg Freezing: 1. Why?; 2. Is it effective?; 3. Is it cost-effective?; 4. When it should be done? ; 5. Are the women the same in different countries?
In this presentation it was discussed the effects of controlled ovarian stimulation (COS) over the endometrium. Moreover, it was discussed the pros and cons of the freeze-all policy.
Workshop on Management of poor prognosis patientsMatheus Roque
In this presentation, it was discussed new concepts in stratification of low prognosis patients. It was also discussed the differences between LH and hCG, and how they can have an influence during COS.
Freeze-all policy: systematic review and meta-analysisMatheus Roque
This study was presented during ASRM2018. This is a systematic review and meta-analysis evaluating the potential clinical, obstetrical and perinatal benefits of the freeze-all policy ver the fresh embryo transfer
In this presentation during 4th National Conference Embriology ISAR, we discussed about the oocyte inefficiency faced by women, evaluated if there is any solution to overcome this problem, and finally suggested an alternative. All of this presenting evidence that the ovarian stimulation is not related to a decrease in embryo quality. Maximizing the number of oocytes retrieved during ovarian stimulation, is the best way to improve the cumulative live birth rates per ovarian stimulation, decreasing the number of ovarian stimulation and oocyte pick-ups necessary to achieve the mainly goal of an IVF treatment: a health live birth
A failed IVF cycle can be because of poor egg quality, sperm quality or uterine lining. It is assumed that all the stimulation egg pick up, laboratory procedures and embryo transfers have been done meticulously in previous attempts. We offer certain modifications in an IVF cycles for optimizing outcome in couples suffering from failed IVF attempts-
Optimized stimulation protocol: The short antagonist protocol offers the best results in terms of selection of the best oocytes (eggs) in most cases.
Selection of Sperm: In many cases, Intra Cytoplasmic Sperm Injection (ICSI) is offered as it has been suggested that it may improve fertilization rates and hence, overall pregnancy outcome. Our embryologist takes special care to select the best sperms for doing ICSI.
Hysteroscopy: The hysteroscope aids us in picking up uterine abnormalities which are sometimes missed at routine ultrasound e.g., small polyps. It is also useful in washing and cleaning the uterus which sometimes may help in improving the outcomes. Endometrial scratching is also done at the same setting to improve the uterine receptivity.
Intravenous Immunoglobulin (IYIg): IVIg seems to directly affect NK cell level and activity, by reducing their absolute numbers and increasing the expression of inhibitory receptors CD94 which potentially can improve pregnancy outcome.
Vitamins and Antioxidants: DHEA, L Arginine, Zinc, selenium etc. are given to women and men as indicated to improve the egg and sperm quality.
Atosiban: This is a uterine relaxant which is given during the embryo transfer. It helps in relaxing the uterus and therefore, improving the endometrial receptivity.
Laser Hatching: Laser hatching of the embryos is performed on the day of embryo transfer to ensure that the shell of the embryo hatches easily. This allows the embryo to implant better. This is mainly suitable for embryos with thick shell, advanced age group and frozen embryos.
ERA: ERA presumably detects the phase of the endometrium in which the embryo best implant. However, there is controversy regarding the actual benefit of this in improving the live birth rate.
PGS: PGS is a way of detecting abnormal embryos thus may help in improving the pregnancy rates. However, each case must be individualized.
Day of Transfer: Not all women will be benefitted by Blastocyst (Day 5 ) transfer as many seem to believe by studying the internet. The day of transfer should be individualized for each patient.
Meticulous Transfer Technique: Embryo transfer is the final and one of the most crucial step of IVF. All embryo transfers at AFGC are performed by Dr Kaberi Banerjee who has taken special training in embryo transfer from UK.
In this presentation, it was discussed: the POSEIDON new concept concerning low prognosis patients; why and when to add or not the LH; differences between LH and hCG; different trigger options; fresh vs freeze-all; and also ICSI with ejaculated vs. testicular sperm in cases of high sperm DNA fragmentation
In this presentation it was discussed the effects of controlled ovarian stimulation (COS) over the endometrium. Moreover, it was discussed the pros and cons of the freeze-all policy.
Workshop on Management of poor prognosis patientsMatheus Roque
In this presentation, it was discussed new concepts in stratification of low prognosis patients. It was also discussed the differences between LH and hCG, and how they can have an influence during COS.
Freeze-all policy: systematic review and meta-analysisMatheus Roque
This study was presented during ASRM2018. This is a systematic review and meta-analysis evaluating the potential clinical, obstetrical and perinatal benefits of the freeze-all policy ver the fresh embryo transfer
In this presentation during 4th National Conference Embriology ISAR, we discussed about the oocyte inefficiency faced by women, evaluated if there is any solution to overcome this problem, and finally suggested an alternative. All of this presenting evidence that the ovarian stimulation is not related to a decrease in embryo quality. Maximizing the number of oocytes retrieved during ovarian stimulation, is the best way to improve the cumulative live birth rates per ovarian stimulation, decreasing the number of ovarian stimulation and oocyte pick-ups necessary to achieve the mainly goal of an IVF treatment: a health live birth
A failed IVF cycle can be because of poor egg quality, sperm quality or uterine lining. It is assumed that all the stimulation egg pick up, laboratory procedures and embryo transfers have been done meticulously in previous attempts. We offer certain modifications in an IVF cycles for optimizing outcome in couples suffering from failed IVF attempts-
Optimized stimulation protocol: The short antagonist protocol offers the best results in terms of selection of the best oocytes (eggs) in most cases.
Selection of Sperm: In many cases, Intra Cytoplasmic Sperm Injection (ICSI) is offered as it has been suggested that it may improve fertilization rates and hence, overall pregnancy outcome. Our embryologist takes special care to select the best sperms for doing ICSI.
Hysteroscopy: The hysteroscope aids us in picking up uterine abnormalities which are sometimes missed at routine ultrasound e.g., small polyps. It is also useful in washing and cleaning the uterus which sometimes may help in improving the outcomes. Endometrial scratching is also done at the same setting to improve the uterine receptivity.
Intravenous Immunoglobulin (IYIg): IVIg seems to directly affect NK cell level and activity, by reducing their absolute numbers and increasing the expression of inhibitory receptors CD94 which potentially can improve pregnancy outcome.
Vitamins and Antioxidants: DHEA, L Arginine, Zinc, selenium etc. are given to women and men as indicated to improve the egg and sperm quality.
Atosiban: This is a uterine relaxant which is given during the embryo transfer. It helps in relaxing the uterus and therefore, improving the endometrial receptivity.
Laser Hatching: Laser hatching of the embryos is performed on the day of embryo transfer to ensure that the shell of the embryo hatches easily. This allows the embryo to implant better. This is mainly suitable for embryos with thick shell, advanced age group and frozen embryos.
ERA: ERA presumably detects the phase of the endometrium in which the embryo best implant. However, there is controversy regarding the actual benefit of this in improving the live birth rate.
PGS: PGS is a way of detecting abnormal embryos thus may help in improving the pregnancy rates. However, each case must be individualized.
Day of Transfer: Not all women will be benefitted by Blastocyst (Day 5 ) transfer as many seem to believe by studying the internet. The day of transfer should be individualized for each patient.
Meticulous Transfer Technique: Embryo transfer is the final and one of the most crucial step of IVF. All embryo transfers at AFGC are performed by Dr Kaberi Banerjee who has taken special training in embryo transfer from UK.
In this presentation, it was discussed: the POSEIDON new concept concerning low prognosis patients; why and when to add or not the LH; differences between LH and hCG; different trigger options; fresh vs freeze-all; and also ICSI with ejaculated vs. testicular sperm in cases of high sperm DNA fragmentation
Ahmed Walid Anwar Morad, Professor Obstetrics and Gynecology
Optional procedures alongside the standard IVF protocol to increase the chance of a live birth.
Free Information Session 5th September 2012: Recent Breakthroughs in IVFFertility SA
Dr Louise Hull spoke about new technologies which are improving outcomes and making fertility treatment a more straightforward process. She covered how they fit into our current treatment plans, the reasons for developing them and the evidence regarding the benefits.
Dr Hull has worked in fertility services since she graduated as a doctor 15 years ago. She became Obstetrician and Gynaecologist (FRANZCOG) after gaining clinical experience in New Zealand and Cambridge and Somerset in the UK. Louise has a strong interest in reproductive medicine and has worked in IVF units in New Zealand, England and Australia, including Bourn Hall, the fertility centre where the first IVF baby was born. For more information about Dr Hull, please follow this link: http://www.fertilitysa.com.au/dr-m.-louise-hull-specialist.html
How to prevent occurrence of severe ovarian hyperstimulation in IVF. Is there a way ? this talk will present a pilot randomised study that may shed the light on this
How to choose between drugs: efficacy / safety and cost effectiveness. In IVF, we have GnRHagonist and antagonists: how to choose based on best available evidence. This talk may help to answer this question
Invited Lecture delivered by Dr Sujoy Dasgupta in National Youth Conference, held at Patna in August 2019. This session was sponsored by Bharat Serum and Vaccines
Progesterone for luteal phase support in IVF cyclesHesham Al-Inany
Luteal phase support is essential for IVF cycles. Progesterone has many forms and modalities: which to use? this talk is an attempt to answer this question
Ahmed Walid Anwar Morad, Professor Obstetrics and Gynecology
Optional procedures alongside the standard IVF protocol to increase the chance of a live birth.
Free Information Session 5th September 2012: Recent Breakthroughs in IVFFertility SA
Dr Louise Hull spoke about new technologies which are improving outcomes and making fertility treatment a more straightforward process. She covered how they fit into our current treatment plans, the reasons for developing them and the evidence regarding the benefits.
Dr Hull has worked in fertility services since she graduated as a doctor 15 years ago. She became Obstetrician and Gynaecologist (FRANZCOG) after gaining clinical experience in New Zealand and Cambridge and Somerset in the UK. Louise has a strong interest in reproductive medicine and has worked in IVF units in New Zealand, England and Australia, including Bourn Hall, the fertility centre where the first IVF baby was born. For more information about Dr Hull, please follow this link: http://www.fertilitysa.com.au/dr-m.-louise-hull-specialist.html
How to prevent occurrence of severe ovarian hyperstimulation in IVF. Is there a way ? this talk will present a pilot randomised study that may shed the light on this
How to choose between drugs: efficacy / safety and cost effectiveness. In IVF, we have GnRHagonist and antagonists: how to choose based on best available evidence. This talk may help to answer this question
Invited Lecture delivered by Dr Sujoy Dasgupta in National Youth Conference, held at Patna in August 2019. This session was sponsored by Bharat Serum and Vaccines
Progesterone for luteal phase support in IVF cyclesHesham Al-Inany
Luteal phase support is essential for IVF cycles. Progesterone has many forms and modalities: which to use? this talk is an attempt to answer this question
Dr. Sunita Chandra, Chairperson & Director-Rajendra Nagar Hospital & IVF Centre and Mopheus Lucknow Fertility Centre gave the talk on IVF PREGNANCY at webinar on March 27,2021
Role of Atosiban In ART,Dr Jyoti Agarwal, Dr. Sharda Jain Lifecare Centre
Exponential increase in IVF Procedures in India
India performs approx 1 Lac IVF cycles annually &
55% of the IVF cycles performed across the top eight metro cities
Mark Perloe, MD Atlanta, 404-843-2229 Learn about the factors that can adversely affect fertility and the tests that can help pinpoint problems. Fertility treatment options including IVF and other high tech options are presented.
MICROBIOME IN ART& Need of Probiotics Dr Sharda Jain Dr Jyoti Agarwal Lifecare Centre
MICROBIOME IN ART& Need of Probiotics Dr Sharda Jain Dr Jyoti Agarwal
WHAT IS MICROBIOME ?
Reproductive system comprises of number of microbes
There number is more than total cells of Genital Tract
These microbes play an important role in maintaining the homeostasis & normal functioning of the Genital Tract
system
Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation in the male foetus.
In women,AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation
Similar to Fertility preservation in addressing women's biological clock and decreasing fertility (20)
Neste apresentação, foram abordadas as principais dúvidas que as pacientes podem ter diante de seu ginecologista, em relação aos fatores da fertilidade masculina.
Congelamento Social: Promessa ou Panacéia?Matheus Roque
Aula apresentada durante o 28o Congresso da Sociedade Brasileira de Reprodução Humana em Belo Horizonte. Apresentando os motivos do congelamento de óvulos social e sua importância
Nesta apresentação são discutidos os principais tópicos relacionados ao efeito da estimulação ovariana realizada nos tratamentos de Fertilização in vitro (FIV) sobre o endométrio. Também é feita uma análise crítica e sucinta sobre o Freeze-all
Avaliação feminina - o que devemos levar em consideração Matheus Roque
Aula ministrada durante o Congresso Brasileiro de Urologia 2017. Foi debatido com os urologistas os principais fatores femininos a serem considerados antes de indicar-se um tratamento para o fator masculino
Quando indicar ou não as Técnicas de Reprodução AssistidaMatheus Roque
Aula apresentada durante o Congresso Brasiliro de Urologiate 2017. Discutido criticamente com urologistas quando indicar ou não as Técnicas de Reprodução Assistida
Papel do LH na indução ovularia: quando e como utilizar. Diretrizes do estudo...Matheus Roque
Nesta apresentação foi demonstrado o racional para o desenvolvimento do conceito POSEIDON. Também foi demonstrado o papel do LH durante a foliculogênese e quando está indicado durante o estímulo ovariano
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Fertility preservation in addressing women's biological clock and decreasing fertility
1. MOBILE
BEST DATA PLANLorem Ipsum has two main statistical methodologies are used in data analysis which
summarizes data from a sample using indexes Tempor mediocrem imperdiet no usu,
tractatos salutatus ut est. Eu vel detraxit laboramus. Cu nam unum liber audiam.
Fertility Preservation inAddressing
Woman’s Biological Clock and
Decreasing fertility
Matheus Roque
ORIGEN – Centro de Medicina Reprodutiva -
BRAZIL
INSIGHT’17
Coimbatore
INDIA
28-29 Oct - 2017
5. 41 years old (2014)
Single
AMH 0.9 ng/mL
June / 2014: 3 mature oocytes vitrified
September / 2014: + 3 oocytes vitrified
FERTILITY PRESERVATION
Should I freeze my eggs?
Fertility preservation in addressing women’s biological clock and decreasing fertility
6. 41 years old
Single
With 6 vitrified oocytes – 2014
FERTILITY PRESERVATION
Should I freeze my eggs?
Fertility preservation in addressing women’s biological clock and decreasing fertility
7. 41 years old
Single
With 6 vitrified oocytes – 2014
FERTILITY PRESERVATION ???
FERTILITY PRESERVATION
Should I freeze my eggs?
Fertility preservation in addressing women’s biological clock and decreasing fertility
OOCYTE CRYOPRESERVATION
Should I freeze my eggs?
8. 41 years old
Single
With 6 vitrified oocytes - 2014
2017 – 44 years old
Amenorrhea; AMH 0.1
OOCYTE CRYOPRESERVATION
Should I freeze my eggs?
Fertility preservation in addressing women’s biological clock and decreasing fertility
9. 41 years old
Single
2014 - With 6 vitrified oocytes
2017 – ICSI with sperm bank
TWINS
OOCYTE CRYOPRESERVATION
Should I freeze my eggs?
Fertility preservation in addressing women’s biological clock and decreasing fertility
10. Presentation Goals
Why?
Is it effective?
Is it cost-effective?
When it should be done?
Are the women the same in different
countries?
12. WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE
Fertility preservation in addressing women’s biological clock and decreasing fertility
13. WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE
Fertility preservation in addressing women’s biological clock and decreasing fertility
14. WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE
Fleming et al., Fertil Steril 2012
NGF
Non-growing follicles
Fertility preservation in addressing women’s biological clock and decreasing fertility
15. Faddy et al., Hum Reprod 1992; Cortvrint et al., Fertil Steril 2001
Birth
Optimal
Fertility
Decreased
Fertility
End of
Fertility
Irregular
menses
0 18 33 36 40 5127
Number of
follicles
1000
10000
100000
1000000
Pathological / Iatrogenic
WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE
Fertility preservation in addressing women’s biological clock and decreasing fertility
16. Pathological Iathrogenic
- Surgery
- Drugs – oncological / non-
oncological treatment
WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE
Fertility preservation in addressing women’s biological clock and decreasing fertility
17. 70% 60% 50% 30% 15%
Ata et al., Reprod Biomed Online 2012
Even with a good ovarian reserve,
there is an important increase in
aneuploidy rates with advanced
maternal age
WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE
Fertility preservation in addressing women’s biological clock and decreasing fertility
18. WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE
Fertility preservation in addressing women’s biological clock and decreasing fertility
19. Fertility preservation in addressing women’s biological clock and decreasing fertility
WHY OOCYTE CRYOPRESERVATION ?
OVARIAN RESERVE and OOCYTE QUALITY
Natural conception at a
relative early age
OOCYTE
CRYOPRESERVATION
20. Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al., Fertil Steril 2016
OOCYTE CRYOPRESERVATION
Trends of Elective Fertility Preservation
% Elective Fertility Preservation vs. Total number of oocyte vitrification
22. OOCYTE CRYOPRESERVATION
Is it effective?
Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al, Fertil Steril 2015
23. OOCYTE CRYOPRESERVATION
Is it effective?
Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al, Fertil Steril 2015
0
10
20
30
40
50
60
70
80
90
100
6 months 6-12 months 12-18 months 18-24 months 24-36 months 36-48 months 48-60 months
39.7 37.9 38.1 38.4 35.6 36
100
%
IMPLANTATION RATE ACCORDING TO STORAGE TIME
Implantation Rate
25. Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al, Fertil Steril 2015
OOCYTE CRYOPRESERVATION
Is it effective?
0
10
20
30
40
50
60
70
80
90
100
5 10 12 15 20 25 30 35 40 43
6.1
39.4
53.5
67.5
80.5
85.4 89.9
94.8 95.5 97.3
%
Cumulative live birth rate according to the number of oocytes
consumed
No. of consumed oocytes
26. Fertility preservation in addressing women’s biological clock and decreasing fertility
The arguments against allowing this
application of the technology are not
convincing
ESHERE Task Force, Hum Reprod 2012
OOCYTE CRYOPRESERVATION
Is it effective?
27. Fertility preservation in addressing women’s biological clock and decreasing fertility
Oocyte vitrification and thawing should no
longer be considered experimental
ASRM, Fertil Steril 2013
OOCYTE CRYOPRESERVATION
Is it effective?
28. Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al., Fertil Steril 2016
OOCYTE CRYOPRESERVATION
Is it effective?
29. Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al., Fertil Steril 2016
OOCYTE CRYOPRESERVATION
Is it effective?
No. of oocytes according to women’s age
30. Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al, Fertil Steril 2016
OOCYTE CRYOPRESERVATION
Is it effective?
0
10
20
30
40
50
60
70
80
90
Survival Rate Embryo transfer
rate / patient
Implantation Rate Ongoing pregnancy
rate / patient
85.2 85.4
35.9
25
%
Clinical outcomes cryopreserved oocytes – elective cryopreservation
Clinical outcomes - Mean age at Fertility Preservation 37.2 years old
31. Fertility preservation in addressing women’s biological clock and decreasing fertility
Doyle et al., Fertil Steril 2016
OOCYTE CRYOPRESERVATION
Is it effective?
32. Fertility preservation in addressing women’s biological clock and decreasing fertility
Doyle et al., Fertil Steril 2016
OOCYTE CRYOPRESERVATION
Is it effective?
0
10
20
30
40
50
60
70
80
Fertilization Rate IR CPR / Transfer LBR / transfer cycle
69.5
41.2
54.4
38.6
71.7
35.4
45.1
36
%
Clinical Outcomes – autologous ICSI cycles with vitrified vs fresh
oocytes
Vitrified Oocytes (n=128) - 34.9 years Fresh Oocytes (n=2963) - 35.5 years
33. Fertility preservation in addressing women’s biological clock and decreasing fertility
Doyle et al., Fertil Steril 2016
OOCYTE CRYOPRESERVATION
Is it effective?
Predicted probability of having at least one, two, and three
children
35. Fertility preservation in addressing women’s biological clock and decreasing fertility
Hirshfeld-Cytron et al., Fertil Steril 2012
OOCYTE CRYOPRESERVATION
Is it cost-effective?
36. Fertility preservation in addressing women’s biological clock and decreasing fertility
Hirshfeld-Cytron et al., Fertil Steril 2012
OOCYTE CRYOPRESERVATION
Is it cost-effective?
Oocyte cryopreservation is not cost-effective for
healthy women planning delayed childbearing
37. Fertility preservation in addressing women’s biological clock and decreasing fertility
Hirshfeld-Cytron et al., Fertil Steril 2012
OOCYTE CRYOPRESERVATION
Is it cost-effective?
Oocyte cryopreservation is not cost-effective for
healthy women planning delayed childbearing
*oocyte cryopreservation at age 25
38. Fertility preservation in addressing women’s biological clock and decreasing fertility
Devineet al., Fertil Steril 2015
OOCYTE CRYOPRESERVATION
Is it cost-effective?
39. Fertility preservation in addressing women’s biological clock and decreasing fertility
Devine et al., Fertil Steril 2015
OOCYTE CRYOPRESERVATION
Is it cost-effective?
40. Fertility preservation in addressing women’s biological clock and decreasing fertility
Devine et al., Fertil Steril 2015
OOCYTE CRYOPRESERVATION
Is it cost-effective?
Oocyte cryopreservation at age 25
41. Fertility preservation in addressing women’s biological clock and decreasing fertility
Van Loendersloot et al., Hum reprod 2012
OOCYTE CRYOPRESERVATION
Is it cost-effective?
42. Fertility preservation in addressing women’s biological clock and decreasing fertility
OOCYTE CRYOPRESERVATION
Is it cost-effective?
Van Loendersloot et al., Hum reprod 2012
43. Presentation Goals
Why? Decrease in ovarian reserve and egg
quality
Is it effective? YES
Is it cost-effective? Controversial; probably
YES
When it should be done?
44. Fertility preservation in addressing women’s biological clock and decreasing fertility
Mesen et al., Fertil Steril 2015
OOCYTE CRYOPRESERVATION
When it should be done?
45. Fertility preservation in addressing women’s biological clock and decreasing fertility
Mesen et al., Fertil Steril 2015
OOCYTE CRYOPRESERVATION
When it should be done?
46. Fertility preservation in addressing women’s biological clock and decreasing fertility
Mesen et al., Fertil Steril 2015
OOCYTE CRYOPRESERVATION
When it should be done?
47. Fertility preservation in addressing women’s biological clock and decreasing fertility
Cobo et al., Fertil Steril 2016
OOCYTE CRYOPRESERVATION
When it should be done?
<= 35y
>= 36y
48. Presentation Goals
Why? Decrease in ovarian reserve and egg
quality
Is it effective? YES
Is it cost-effective? Controversial; probably
YES
When it should be done? < 35-37 years old
49. Presentation Goals
Why? Decrease in ovarian reserve and egg
quality
Is it effective? YES
Is it cost-effective? Controversial; probably
YES
When it should be done? < 35-37 years old
Are there differences in different ethinicity?
50. Fertility preservation in addressing women’s biological clock and decreasing fertility
Iglesias et al., Fertil Steril 2014
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
51. Fertility preservation in addressing women’s biological clock and decreasing fertility
Iglesias et al., Fertil Steril 2014
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
52. Fertility preservation in addressing women’s biological clock and decreasing fertility
Iglesias et al., Fertil Steril 2014
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
53. Fertility preservation in addressing women’s biological clock and decreasing fertility
Iglesias et al., Fertil Steril 2014
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
54. Fertility preservation in addressing women’s biological clock and decreasing fertility
Iglesias et al., Fertil Steril 2014
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
Total gonadotropin (IU) 2,420 840 2,910 902 <.001
INDIAN WOMEN: 6-year advancement in ovarian aging
Sub-optimal response
55. Fertility preservation in addressing women’s biological clock and decreasing fertility
Maalouf et al., BJOG 2016
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
United Kingdom (UK) Database
2000 to 2010: 38,709 women
Live birth rate and the effect of ethnicity
56. Fertility preservation in addressing women’s biological clock and decreasing fertility
Maalouf et al., BJOG 2016
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
57. If true biologic differences exist, they may profoundly affect
patient counseling and the adaptation of COS protocols to
biologic age rather than chronologic age
Iglesias et al., 2014
Fertility preservation in addressing women’s biological clock and decreasing fertility
Maalouf et al., BJOG 2016
OOCYTE CRYOPRESERVATION
Are there differences in different ethinicity?
58. Presentation Goals
Why? Decrease in ovarian reserve and egg
quality
Is it effective? YES
Is it cost-effective? Controversial; probably
YES
When it should be done? < 35-37 years old
Are there differences in different ethinicity?
Probably YES
59. Fertility preservation in addressing women’s biological clock and decreasing fertility
Is this the perfect strategy to make sure a
woman will delivery a baby in the future ???
OOCYTE CRYOPRESEVATION
But so far, this is the BEST strategy to
increase the chances of delivering a baby
with own oocytes in the future
60. TAKE –HOME MESSAGES
OOCYTE CRYOPRESERVATION
Oocyte vitrification should not be considered as experimental
It is not the guarantee of future pregnancy, but can really
increase the chance
Adequate information / avoid raising false hopes
The final decision is not ours but the patient's
The women should be advised about Oocyte
Cryopreservation
61. Corpo Clínico:
Marcello Valle
Selmo Geber
Marcos Sampaio
Matheus Roque
Rodolfo Salvato
Alessandra Kostolias
Rafaela Batisti
Mauro Bellece
Monique Ubaldo
Ana Carolina Iacob
Rodrigo Abud
Nilson Lama
Françoise Padula
Thank you!
matheusroque@origen.com.br
pt.slideshare.net/MatheusRoque1
Laboratório:
Brunna Vaz
Lucas Nazareth
Ana Carolina Pontes
Thaiza
Psicologia:
Sheila Veloso
Enfermagem:
Karla Santiago
Adriana Janotti
Thais Bastos
Joana Paes
Marcelle
Nutrição:
Camilla Estima